R&D When is the superbug message going to bite? As existing antibiotics become less effective, we edge closer to a future where routine infections & minor injuries could once again become high risk.
News Shionogi puts up to $600m behind BioVersys antibiotics Shionogi has added to its antibiotics pipeline by taking an option on a preclinical-stage candidate from BioVersys for non-tuberculous mycobacteria.
News Wockhardt has high hopes for novel antibiotic Zaynich Wockhardt has completed a pre-filing meeting with the FDA and is preparing to submit its novel antibiotic Zaynich in the US and Europe.
News Data sets up filing of new GSK antibiotic this year GSK has said it will file its oral carbapenem antibiotic tebipenem HBr for approval before the end of this year as a treatment for complicated UTIs.
Market Access Reuters Europe 2025: Using value propositions to improve acc... In a Reuters Pharma Europe 2025 fireside chat, NICE Advice Director Brad Grove spoke with Novartis's Matic Meglic about novel pharma payment models.
R&D Jennifer Schneider’s insights on immunotherapy at JP Morgan ... Jonah Comstock caught up with Jennifer Schneider, CEO of Centauri Therapeutics, in San Francisco in January during the JP Morgan Healthcare Conference
News UK project addresses capacity issue in CGT manufacturing A UK consortium has been set up to tackle a major issue in the development of cell and gene therapies (CGT) – a lack of manufacturing capacity.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face